69660-38-4

Basic information

• Product Name: 5-Hydroxy-3-methoxy-4-methylbenzoesaeure-methylester
• Synonyms: 5-Hydroxy-3-methoxy-4-methylbenzoesaeure-methylester
• CAS NO: 69660-38-4
• Molecular Weight: 196.203
• Mol File: 69660-38-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 5-Hydroxy-3-methoxy-4-methylbenzoesaeure-methylester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Hydroxy-3-methoxy-4-methylbenzoesaeure-methylester(69660-38-4)
• EPA Substance Registry System: 5-Hydroxy-3-methoxy-4-methylbenzoesaeure-methylester(69660-38-4)

Safety Data

• Hazardous Substances Data: 69660-38-4(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 72922-62-4 3-hydroxy-5-methoxy-4-methyl-benzoic acid 
• 75238-29-8 3,5-dihydroxy-4-methylbenzoic acid methyl ester 
• 74-88-4 methyl iodide 
• 28026-96-2 3,5-dihydroxy-4-methylbenzoic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 52231-37-5 4,6-Dihydroxy-5-methyl-1(3H)-isobenzofuranon 
• 301530-16-5 3-benzyloxy-5-methoxy-4-methylstyrene 
• 301530-15-4 3-(benzyloxy)-5-methoxy-4-methylbenzaldehyde 
• 72922-69-1 methyl 3-(benzyloxy)-5-methoxy-4-methylbenzoate 

Relevant articles and documents

Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY

Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa

The present invention relates to compounds comprising the following formula: R0—Q—X—Q′—W—U—V—G—M??(I) These compounds are useful as pharmacologically active compounds. They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders such as thromboembolic diseases or restenoses. These compounds are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can generally be used to treat, prevent, or cure conditions in which an undesired activity of factor Xa and/or factor VIIa is present, or where inhibition of factor Xa and/or factor VIIa is intended. The invention further relates to processes for the preparation of these compounds, methods of their use (e.g., as active ingredients in pharmaceuticals), and pharmaceutical preparations comprising them.

Metabolites from microorganisms, XXX. Phthalides and chromanols from Aspergillus duricaulis

-